EA004808B1 - Биодоступная лекарственная форма изотретиноина - Google Patents

Биодоступная лекарственная форма изотретиноина Download PDF

Info

Publication number: EA004808B1
Authority: EA; Eurasian Patent Office
Prior art keywords: less; particle size; acid; oil; acid form
Prior art date: 2000-06-16

Application number

EA200200166A

Other languages

English (en)

Russian (ru)

Other versions

EA200200166A1 (ru

Inventor

Абха Пант

Индердип Бхатия

Суниленду Бхусхан Рой

Раджив Малик

Original Assignee

Рэнбакси Лабораториз Лимитед

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-16

Filing date

2001-04-09

Publication date

2004-08-26

2001-04-09 Application filed by Рэнбакси Лабораториз Лимитед filed Critical Рэнбакси Лабораториз Лимитед

2002-10-31 Publication of EA200200166A1 publication Critical patent/EA200200166A1/ru

2004-08-26 Publication of EA004808B1 publication Critical patent/EA004808B1/ru

Links

SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title abstract description 20
229960005280 isotretinoin Drugs 0.000 title abstract description 20
239000002552 dosage form Substances 0.000 title abstract description 4
239000000203 mixture Substances 0.000 claims abstract description 58
239000002245 particle Substances 0.000 claims abstract description 48
239000002253 acid Substances 0.000 claims abstract description 37
238000000034 method Methods 0.000 claims abstract description 30
239000000375 suspending agent Substances 0.000 claims abstract description 20
239000003814 drug Substances 0.000 claims abstract description 17
229940079593 drug Drugs 0.000 claims abstract description 12
239000003963 antioxidant agent Substances 0.000 claims abstract description 10
235000006708 antioxidants Nutrition 0.000 claims abstract description 10
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
239000004322 Butylated hydroxytoluene Substances 0.000 claims abstract description 6
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims abstract description 6
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 6
235000010354 butylated hydroxytoluene Nutrition 0.000 claims abstract description 6
229940095259 butylated hydroxytoluene Drugs 0.000 claims abstract description 6
239000008172 hydrogenated vegetable oil Substances 0.000 claims abstract description 6
238000002156 mixing Methods 0.000 claims abstract description 6
229940045860 white wax Drugs 0.000 claims abstract description 6
235000019483 Peanut oil Nutrition 0.000 claims abstract description 5
235000019282 butylated hydroxyanisole Nutrition 0.000 claims abstract description 5
239000000084 colloidal system Substances 0.000 claims abstract description 5
235000012343 cottonseed oil Nutrition 0.000 claims abstract description 5
239000002385 cottonseed oil Substances 0.000 claims abstract description 5
239000002480 mineral oil Substances 0.000 claims abstract description 5
235000010446 mineral oil Nutrition 0.000 claims abstract description 5
239000000312 peanut oil Substances 0.000 claims abstract description 5
239000008159 sesame oil Substances 0.000 claims abstract description 5
235000011803 sesame oil Nutrition 0.000 claims abstract description 5
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 4
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 4
235000004835 α-tocopherol Nutrition 0.000 claims abstract description 4
239000004255 Butylated hydroxyanisole Substances 0.000 claims abstract 4
239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims abstract 4
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims abstract 4
235000010385 ascorbyl palmitate Nutrition 0.000 claims abstract 4
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims abstract 4
229940043253 butylated hydroxyanisole Drugs 0.000 claims abstract 4
SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims abstract 3
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 13
FPIPGXGPPPQFEQ-HWCYFHEPSA-N 13-cis-retinol Chemical compound OC/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HWCYFHEPSA-N 0.000 claims description 13
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
239000008139 complexing agent Substances 0.000 claims description 6
239000003549 soybean oil Substances 0.000 claims description 6
235000012424 soybean oil Nutrition 0.000 claims description 6
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
239000008173 hydrogenated soybean oil Substances 0.000 claims description 4
229940087168 alpha tocopherol Drugs 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
235000010388 propyl gallate Nutrition 0.000 claims description 3
239000000473 propyl gallate Substances 0.000 claims description 3
229940075579 propyl gallate Drugs 0.000 claims description 3
229960000984 tocofersolan Drugs 0.000 claims description 3
239000002076 α-tocopherol Substances 0.000 claims description 3
238000000227 grinding Methods 0.000 claims description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
229960001484 edetic acid Drugs 0.000 claims 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 claims 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
239000010695 polyglycol Substances 0.000 claims 1
229920000151 polyglycol Polymers 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 2
238000009472 formulation Methods 0.000 abstract 12
244000068988 Glycine max Species 0.000 abstract 4
235000010469 Glycine max Nutrition 0.000 abstract 4
239000003795 chemical substances by application Substances 0.000 abstract 4
239000003921 oil Substances 0.000 abstract 4
235000019198 oils Nutrition 0.000 abstract 4
239000007963 capsule composition Substances 0.000 abstract 2
238000007796 conventional method Methods 0.000 abstract 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
238000003801 milling Methods 0.000 abstract 1
239000011732 tocopherol Substances 0.000 abstract 1
150000003772 α-tocopherols Chemical class 0.000 abstract 1
239000008186 active pharmaceutical agent Substances 0.000 description 21
229940088679 drug related substance Drugs 0.000 description 21
238000012360 testing method Methods 0.000 description 7
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000004297 night vision Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EA200200166A 2000-06-16 2001-04-09 Биодоступная лекарственная форма изотретиноина EA004808B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN596DE2000 IN192188B (2)	2000-06-16	2000-06-16
PCT/IB2001/000581 WO2001095886A1 (en)	2000-06-16	2001-04-09	Bioavailable dosage form of isotretinoin

Publications (2)

Publication Number	Publication Date
EA200200166A1 EA200200166A1 (ru)	2002-10-31
EA004808B1 true EA004808B1 (ru)	2004-08-26

Family

ID=11097063

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA200200166A EA004808B1 (ru)	2000-06-16	2001-04-09	Биодоступная лекарственная форма изотретиноина

Country Status (25)

Country	Link
US (1)	US6740337B2 (2)
EP (1)	EP1294357A1 (2)
JP (1)	JP2004503493A (2)
CN (1)	CN1196475C (2)
AP (1)	AP2002002423A0 (2)
AU (1)	AU782094B2 (2)
BG (1)	BG106414A (2)
BR (1)	BR0106752A (2)
CA (1)	CA2382065A1 (2)
CZ (1)	CZ2002694A3 (2)
EA (1)	EA004808B1 (2)
EE (1)	EE200200074A (2)
HK (1)	HK1052302A1 (2)
HR (1)	HRP20020148A2 (2)
HU (1)	HUP0203717A3 (2)
IL (1)	IL148176A0 (2)
IN (1)	IN192188B (2)
MX (1)	MXPA02001669A (2)
NZ (1)	NZ517142A (2)
OA (1)	OA12008A (2)
PL (1)	PL352838A1 (2)
SK (1)	SK2252002A3 (2)
UA (1)	UA74793C2 (2)
WO (1)	WO2001095886A1 (2)
ZA (1)	ZA200201240B (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002024172A1 (en) *	2000-09-22	2002-03-28	Galephar M/F	Pharmaceutical semi-solid composition of isotretinoin
EP1527774A1 (en)	2003-11-03	2005-05-04	Basilea Pharmaceutica AG	New formulation for retinoid-containing soft gelatin capsules
US20070099996A1 (en) *	2003-05-20	2007-05-03	Shashikanth Isloor	Pharmaceutical compositions of acitretin
US20070254025A1 (en) *	2006-04-27	2007-11-01	Cronk Peter J	Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US20070254858A1 (en) *	2006-04-27	2007-11-01	Cronk Peter J	Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
RU2322998C1 (ru) *	2006-11-16	2008-04-27	Общество с ограниченной ответственностью "Березовый мир"	Носитель лекарственных и диагностических средств
JP4588791B2 (ja) *	2007-02-16	2010-12-01	あすか製薬株式会社	微粒子油性懸濁液を含む医薬組成物
US7763748B2 (en) *	2007-02-20	2010-07-27	Ipca Laboratories Limited	Process for preparation of highly pure isotretinoin
US9078925B2 (en)	2012-06-18	2015-07-14	Galephar Pharmaceutical Research, Inc.	Pharmaceutical semi-solid composition of isotretinoin
WO2016189481A1 (en) *	2015-05-25	2016-12-01	Sun Pharmaceutical Industries Limited	Once daily oral pharmaceutical composition of isotretinoin
WO2017203365A1 (en)	2016-05-26	2017-11-30	Dr. Reddy's Laboratiories Ltd.	Pharmaceutical compositions for treating acne
WO2024006748A1 (en) *	2022-07-01	2024-01-04	Acrotech Biopharma Inc.	Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4016254A (en) *	1972-05-19	1977-04-05	Beecham Group Limited	Pharmaceutical formulations
CA1282326C (en) *	1984-12-14	1991-04-02	Paul J. Jarosz	Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
US4808630A (en) *	1987-01-16	1989-02-28	United States Of America	Method of treating psychotic illnesses
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
PE20001227A1 (es) *	1998-10-30	2000-11-06	Hoffmann La Roche	Procesos para producir una composicion de isotretinoina
US6284283B1 (en) *	1999-10-21	2001-09-04	Alkermes Controlled Therapeutics, Inc.	Method of producing sub-micron particles of biologically active agents and uses thereof

2000
- 2000-06-16 IN IN596DE2000 patent/IN192188B/en unknown
2001
- 2001-04-09 EP EP01917381A patent/EP1294357A1/en not_active Withdrawn
- 2001-04-09 EA EA200200166A patent/EA004808B1/ru not_active IP Right Cessation
- 2001-04-09 US US09/829,246 patent/US6740337B2/en not_active Expired - Fee Related
- 2001-04-09 OA OA1200200055A patent/OA12008A/fr unknown
- 2001-04-09 CA CA002382065A patent/CA2382065A1/en not_active Abandoned
- 2001-04-09 AU AU44459/01A patent/AU782094B2/en not_active Ceased
- 2001-04-09 HU HU0203717A patent/HUP0203717A3/hu unknown
- 2001-04-09 AP APAP/P/2002/002423A patent/AP2002002423A0/en unknown
- 2001-04-09 EE EEP200200074A patent/EE200200074A/xx unknown
- 2001-04-09 BR BR0106752-4A patent/BR0106752A/pt not_active IP Right Cessation
- 2001-04-09 IL IL14817601A patent/IL148176A0/xx unknown
- 2001-04-09 CN CNB018024173A patent/CN1196475C/zh not_active Expired - Fee Related
- 2001-04-09 HK HK03104641.2A patent/HK1052302A1/zh unknown
- 2001-04-09 PL PL01352838A patent/PL352838A1/xx not_active Application Discontinuation
- 2001-04-09 NZ NZ517142A patent/NZ517142A/en unknown
- 2001-04-09 MX MXPA02001669A patent/MXPA02001669A/es active IP Right Grant
- 2001-04-09 JP JP2002510065A patent/JP2004503493A/ja active Pending
- 2001-04-09 HR HR20020148A patent/HRP20020148A2/hr not_active Application Discontinuation
- 2001-04-09 WO PCT/IB2001/000581 patent/WO2001095886A1/en not_active Ceased
- 2001-04-09 SK SK225-2002A patent/SK2252002A3/sk unknown
- 2001-04-09 CZ CZ2002694A patent/CZ2002694A3/cs unknown
- 2001-09-04 UA UA2002031946A patent/UA74793C2/uk unknown
2002
- 2002-02-13 ZA ZA200201240A patent/ZA200201240B/en unknown
- 2002-02-14 BG BG06414A patent/BG106414A/xx unknown

Also Published As

Publication number	Publication date
OA12008A (en)	2006-04-19
AU4445901A (en)	2001-12-24
WO2001095886A1 (en)	2001-12-20
HUP0203717A2 (hu)	2003-04-28
JP2004503493A (ja)	2004-02-05
HUP0203717A3 (en)	2003-05-28
HK1052302A1 (zh)	2003-09-11
IL148176A0 (en)	2002-09-12
CZ2002694A3 (cs)	2002-08-14
UA74793C2 (en)	2006-02-15
ZA200201240B (en)	2002-09-02
CN1196475C (zh)	2005-04-13
US6740337B2 (en)	2004-05-25
US20020025338A1 (en)	2002-02-28
SK2252002A3 (en)	2002-08-06
HRP20020148A2 (en)	2003-12-31
BG106414A (en)	2002-09-30
NZ517142A (en)	2003-08-29
IN192188B (2)	2004-03-13
BR0106752A (pt)	2002-04-16
EA200200166A1 (ru)	2002-10-31
EE200200074A (et)	2003-04-15
PL352838A1 (en)	2003-09-08
MXPA02001669A (es)	2002-08-06
CN1388757A (zh)	2003-01-01
AU782094B2 (en)	2005-06-30
CA2382065A1 (en)	2001-12-20
AP2002002423A0 (en)	2002-03-31
EP1294357A1 (en)	2003-03-26

Legal Events

Date	Code	Title	Description
2006-02-24	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM
2007-02-27	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): RU

Publication	Publication Date	Title
US4751241A (en)	1988-06-14	Pharmaceutical composition of cyclandelate having a high degree of bioavailability
KR20060066665A (ko)	2006-06-16	연질캡슐제
EP0184942A2 (en)	1986-06-18	Improved pharmaceutical composition containing 13-CIS vitamin a acid as the active ingredient
TW201114766A (en)	2011-05-01	Pharmaceutical composition for a hepatitis C viral protease inhibitor
EP2680826A1 (en)	2014-01-08	Vitamin d composition
US6740337B2 (en)	2004-05-25	Bioavailable dosage form of isotretinoin
JPS6230965B2 (2)	1987-07-06
US20050129773A1 (en)	2005-06-16	Isotretinoin nanoparticulate compositions
MX2013013575A (es)	2014-09-15	Composicion farmaceutica que comprende fenofenadina.
CN110856712B (zh)	2021-11-30	丁苯酞自微乳组合物及其制备方法和用途
EP0868174B1 (en)	2002-11-20	Oral gel capsule formulation of 1,2,4-benzotriazine oxides
CN119789850A (zh)	2025-04-08	包含异维甲酸的药物组合物及其制备方法和用途
CN118304270B (zh)	2025-03-07	一种维生素d滴剂及其制备方法
TW202128150A (zh)	2021-08-01	３＇—［（２ｚ）—［１—（３，４—二甲基苯基）—１，５—二氫—３—甲基—５—側氧基—４ｈ—吡唑—４—亞基］肼基］—２＇—羥基—［１，１＇—聯苯基］—３—甲酸及其鹽配製物
EP4717262A1 (en)	2026-04-01	Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
JPH07116037B2 (ja)	1995-12-13	ビタミンｅ製剤組成物
EP4717261A1 (en)	2026-04-01	Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
EP4640211A1 (en)	2025-10-29	Pharmaceutical composition comprising water-insoluble vitamin and mixed micelles
GB2029216A (en)	1980-03-19	Compositions containing xanthan gum
CN118304279A (zh)	2024-07-09	一种骨化三醇自微乳口溶膜及其制备方法
EP4312985A1 (en)	2024-02-07	Vitamin d formulations
TW201311239A (zh)	2013-03-16	包含非索非那定（ｆｅｘｏｆｅｎａｄｉｎｅ）之醫藥組成物
CN102697723A (zh)	2012-10-03	一种甲基斑蝥胺脂肪乳剂及其制备方法